Antibody response after application of a new live attenuated mumps vaccine (Pariorix®) measured by enzyme‐linked immunosorbent assay (ELISA)

Popow‐Kraupp, Therese; Künz, Christian; Hofmann, H

doi:10.1002/jmv.1890100206

Cited by 8 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 8th grade students, in a Swiss study, 87% of the children tested seropositive for mumps-specific antibodies [10], similar to our findings. The prevalence of mumps IgG antibodies in a randomly selected population of children aged 1-17 years determined by ELISA showed that mumps antibodies were acquired at an early age [11].…”

Section: Discussionsupporting

confidence: 90%

Seroprevalence of mumps before inclusion of mumps vaccination in the Iranian Expanded Programme on Immunization

Avijgan¹,

Habibian²,

Kheiri³

2009

East Mediterr Health J

View full text Add to dashboard Cite

The current target groups for measles, mumps and rubella vaccination in the Islamic Republic of Iran are children at 12 months and 4-6 years. A study of the age-specific seroprevalence of antibodies against mumps in children aged 3-18 years in Shahrekord aimed to establish the need for booster vaccinations to cover non-immune children. Of 338 children, 19.8% were seronegative. Age-specific seronegativity was 33.3%, 20.5% and 4.6% in age groups 7-11, 12-14 and 15-18 years respectively. To obtain herd immunity, we suggest that for the next 5 years children aged 7-11 years entering guidance school are selected as the main group for vaccination. Séroprévalence des oreillons avant l'intégration de la vaccination anti-ourlienne dans le programme élargi de vaccination iranien RÉSUMÉ À l'heure actuelle, les groupes visés par la vaccination contre la rougeole, les oreillons et la rubéole en République islamique d'Iran sont les enfants âgés de 12 mois et ceux âgés de 4 à 6 ans. Une étude de la séroprévalence par âge des oreillons chez les enfants âgés de 3 à 18 ans a été menée à Shahrekord, dans le but de déterminer s'il y avait lieu de procéder à des vaccinations de rappel afin de protéger les enfants non immunisés. Sur 338 enfants, 19,8 % étaient séronégatifs. La séronégativité selon le critère de l'âge était respectivement de 33,3 %, 20,5 % et 4,6 % dans les groupes de sujets âgés de 7 à 11 ans, de 12 à 14 ans et de 15 à 18 ans. Pour obtenir une immunité collective, nous suggérons que pendant les 5 prochaines années, le principal groupe vacciné soit les enfants âgés de 7 à 11 ans, avant leur entrée dans le second degré. Seroprevalence of mumps ‫للتمنيع‬ ‫ع‬

show abstract

Section: Discussionsupporting

confidence: 90%

Seroprevalence of mumps before inclusion of mumps vaccination in the Iranian Expanded Programme on Immunization

Avijgan¹,

Habibian²,

Kheiri³

2009

East Mediterr Health J

View full text Add to dashboard Cite

show abstract

“…Enzyme immunoassays have been used widely for measuring viral antibodies [Leinikki et al, 1979;Popow-Kraupp et al, 1982;Ukkonen et al, 1980;Vaheri et al, 19821 and EIA has been found to be more sensitive than the SRH or HI methods especially when the antibody response induced by vaccination has been studied [Leinikki et al, 1979;Popow-Kraupr et al, 1982;Vaananen et al, 19761. We found EIA to be a sensitive and reliable method for detecting mumps antibodies also in postvaccination sera.…”

Section: Discussionmentioning

confidence: 99%

Antibody responses to mumps virus proteins in natural mumps infection and after vaccination with live and inactivated mumps virus vaccines

Julkunen

Väänänen

Penttinen

1984

Journal of Medical Virology

View full text Add to dashboard Cite

Paired sera from 20 patients with acute mumps infection, 16 from persons vaccinated with live attenuated mumps virus vaccine, and 12 from persons vaccinated with formalin-inactivated virus vaccine were studied for mumps antibodies by single radial hemolysis (SRH), hemagglutination inhibition (HI), and by enzyme immunoassays (EIA) specific for whole virus, envelope glycoprotein, and nucleocapsid antibodies. Mumps patients had diagnostic rises in serum mumps antibodies in 90-100% of the cases depending on the method of assay. Vaccination resulted in seroconversion in 75-88% (live vaccine) and in 92% (inactivated vaccine) of the cases as detected by SRH or EIAs, whereas HI detected seroconversion only in 38% and 58% of the cases, respectively. Immunoprecipitation analyses revealed that all sera from mumps patients and nearly all postvaccination sera had antibodies against the main structural proteins of mumps virus. By immunoblotting, antibodies against denatured hemagglutinin-neuraminidase (HN) and fusion protein (F) were detected in 15-25% of mumps patients and persons vaccinated with live vaccine, whereas most postvaccination sera from those vaccinated with inactivated vaccine had HN (92%) and F (83%) protein antibodies, suggesting that antibodies against the denatured form of proteins are formed.

show abstract

“…A traditional vaccine approach has succeeded for measles and mumps viruses, so there are several effective live attenuated measles and mumps vaccines approved that are usually applied as a trivalent vaccine against measles, mumps and rubella. They were developed from wild-type isolates mostly in the 1960s [14][15][16][17][18] and have been in use for more than half a century. Meanwhile, pathogen evolution has continued generating new variants under the influence of vaccine-driven evolutionary pressure, and while measles and rubella vaccines seem to resist the evolutionary pressure, the mumps vaccine shows signs NSVs globally cause a large number of infections, with symptoms ranging from a mild infection to life-threatening illness.…”

Section: Introductionmentioning

confidence: 99%

The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral Nucleocapsid

Šantak

Matić

2022

Viruses

View full text Add to dashboard Cite

Negative-stranded RNA viruses (NSVs) are important human pathogens, including emerging and reemerging viruses that cause respiratory, hemorrhagic and other severe illnesses. Vaccine design traditionally relies on the viral surface glycoproteins. However, surface glycoproteins rarely elicit effective long-term immunity due to high variability. Therefore, an alternative approach is to include conserved structural proteins such as nucleoprotein (NP). NP is engaged in myriad processes in the viral life cycle: coating and protection of viral RNA, regulation of transcription/replication processes and induction of immunosuppression of the host. A broad heterosubtypic T-cellular protection was ascribed very early to this protein. In contrast, the understanding of the humoral immunity to NP is very limited in spite of the high titer of non-neutralizing NP-specific antibodies raised upon natural infection or immunization. In this review, the data with important implications for the understanding of the role of NP in the immune response to human NSVs are revisited. Major implications of the elicited T-cell immune responses to NP are evaluated, and the possible multiple mechanisms of the neglected humoral response to NP are discussed. The intention of this review is to remind that NP is a very promising target for the development of future vaccines.

show abstract

Antibody response after application of a new live attenuated mumps vaccine (Pariorix®) measured by enzyme‐linked immunosorbent assay (ELISA)

Cited by 8 publications

References 15 publications

Seroprevalence of mumps before inclusion of mumps vaccination in the Iranian Expanded Programme on Immunization

Seroprevalence of mumps before inclusion of mumps vaccination in the Iranian Expanded Programme on Immunization

Antibody responses to mumps virus proteins in natural mumps infection and after vaccination with live and inactivated mumps virus vaccines

The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses—Not Just Another Brick in the Viral Nucleocapsid

Contact Info

Product

Resources

About